An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Obesity

Volumn 21, Issue 8, 2013, Pages 1561-1570

  Fuller, Nicholas R ^a   Pearson, Suzanne ^a   Lau, Namson S ^a   Wlodarczyk, John ^b   Halstead, Michael B ^c   Tee, Hoi Poh ^d   Chettiar, Raman ^d   Kaffes, Arthur J ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b John Wlodarczyk Consulting Services   (Australia)

^c Allergan Australia   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL PAIN; ADULT; ARTICLE; BEHAVIOR THERAPY; BODY MASS; BODY WEIGHT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DEVICE REMOVAL; EXERCISE TOLERANCE; FEEDING BEHAVIOR; FEMALE; GASTRIC BALLOON; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; METABOLIC SYNDROME X; NAUSEA; OBESITY; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; TREATMENT RESPONSE; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; CHOLESTEROL; DIET; EXERCISE; FEMALE; GASTRIC BALLOON; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84883145904     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20414     Document Type: Article

References (40)

1. WHO. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, Switzerland: World Health Organization; 2009. Contract No.: ISBN 978-92-4-156387-1.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
3. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523-530.
4. Goldstein DJ,. Beneficial health-effects of modest weight-loss. Int J Obes 1992; 16: 397-415.
5. Dansinger ML, Tatsioni A, Wong JB, et al. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007; 147: 41-50.
6. Li ZP, Maglione M, Tu WL, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
7. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Br Med J 2007; 335: 1194-1199.
8. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
9. Nieben OG, Harboe H,. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet 1982; 1: 198-199.
10. Geliebter A, Melton PM, McCray RS, et al. Clinical trial of silicone-rubber gastric balloon to treat obesity. Int J Obes 1991; 15: 259-266.
11. Geliebter A,. Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 1988; 44: 665-668.
12. Mui WLM, Ng EKW, Tsung BYS, et al. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg 2010; 20: 1128-1132.
13. Gottig S, Daskalakis M, Weiner S, et al. Analysis of safety and efficacy of intragastric balloon in extremely obese patients. Obes Surg 2009; 19: 677-683.
14. Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg 2008; 18: 989-992.
15. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg 2005; 15: 1161-1164.
16. Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg 2009; 19: 1084-1088.
17. Al-Momen A, El-Mogy I,. Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg 2005; 15: 101-105.
18. Evans JD, Scott MH,. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg 2001; 88: 1245-1248.
19. Roman S, Napoleon B, Mion F, et al. Intragastric balloon for "non-morbid" obesity: A retrospective evaluation of tolerance and efficacy. Obes Surg 2004; 14: 539-544.
20. Donadio F, Sburlati LF, Masserini B, et al. Metabolic parameters after BioEnterics intragastric balloon placement in obese patients. J Endocrinol Invest 2009; 32: 165-168.
21. Mathus-Vliegen EMH, Tytgat GNJ,. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61: 19-27.
22. Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: A prospective study on 100 patients. Obes Surg 2010; 20: 1496-500.
23. Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 2012; 22: 565-571.
24. Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005; 15: 864-870.
25. Ford ES, Giles WH, Dietz WH,. Prevalence of the metabolic syndrome among US adults-Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
26. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med 2001; 344: 1343-1350.
27. Allergan. The ORBERA™ Intragastric Balloon System-Directions For Use (DFU). 2011 [cited 2011 Dec]; Available from: http://www.allergan.com.au/ Products/Overview.aspx.
28. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk-a new measure of exercise capacity in patients with chronic heart-failure. Can Med Assoc J 1985; 132: 919-923.
29. Kolotkin RL, Crosby RD, Kosloski KD, et al. Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102-111.
30. Cappelleri JC, Bushmakin AG, Gerber RA, et al. Psychometric analysis of the Three-Factor Eating Questionnaire-R21: results from a large diverse sample of obese and non-obese participants. Int J Obes 2009; 33: 611-620.
31. Dixon JB, Dixon ME,. Combined strategies in the management of obesity. Asia Pac J Clin Nutr 2006; 15 (Suppl): 63-69.
32. Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg 2008; 18: 841-846.
33. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.
34. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-1128.
35. McNulty SJ, Ur E, Williams G, et al. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with mefformin. Diabetes Care 2003; 26: 125-131.
36. de Leiva A,. What are the benefits of moderate weight loss? Exp Clin Endocrinol Diabetes 1998; 106: 10-13.
37. Hirani V, Zaninotto P, Primatesta P,. Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension-diabetes co-morbidity in England. Public Health Nutr 2008; 11: 521-527.
38. Bray GA, Chatellier A, Duncan C, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-1686.
39. Crosby RD, Kolotkin RL, Williams GR,. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol 2004; 57: 1153-1160.
40. Mion F, Napoleon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg 2005; 15: 510-516.